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Granzyme B is important for the ability of NK
cells and CD8+ T cells to kill their targets.
However, we showed here that granzyme B-
deficient mice clear both allogeneic and synge-
neic tumor cell lines more efficiently than do
wild-type (WT) mice. To determine whether
regulatory T (Treg) cells utilize granzyme B to
suppress immune responses against these tu-
mors, we examined the expression and function
of granzyme B in Treg cells. Granzyme B was
not expressed in naive Treg cells but was highly
expressed in 5%–30% of CD4+Foxp3+ Treg
cells in the tumor environment. Adoptive trans-
fer ofWT Treg cells, but not granzymeB- or per-
forin-deficient Treg cells, into granzyme B-defi-
cient mice partially restored susceptibility to
tumor growth; Treg cells derived from the tumor
environment could induce NK and CD8+ T cell
death in a granzyme B- and perforin-dependent
fashion. Granzyme B and perforin are therefore
relevant for Treg cell-mediated suppression of
tumor clearance in vivo.
INTRODUCTION
Many studies have established that cell-mediated innate
and adaptive immunity are essential for preventing pri-
mary tumor outgrowth and for rejecting transplanted
tumors (Dunn et al., 2004a; Pardoll, 2003). Natural killer
(NK) cells are innate immune effectors that can kill MHC
class I-deficient (MHC I–) tumor cell lines in vivo (Karre
et al., 1986; Smyth et al., 2000a).Mice genetically deficient
for NK cells display severe defects in the clearance of
MHC I– tumor cells (Kim et al., 2000). In addition, mice de-
pleted of NK cells are more susceptible to chemically
induced tumors (Smyth et al., 2001). Adoptive transfer
studies have established that CD8+ T cells, asmajor effec-
tors for antigen-specific antitumor immunity, can recog-
nize and kill malignant cells that present antigen peptideswith MHC I molecules (Gorelik and Flavell, 2001; Okada
et al., 1997). At the molecular level, the granule exocytosis
pathway and Fas-FasL system account for virtually all of
the measurable contact-mediated cytotoxicity delivered
by NK and CD8+ T cells (Lieberman, 2003; Russell and
Ley, 2002). The granule exocytosis pathway utilizes per-
forin to traffic granzymes appropriately into the cytosol
(Keefe et al., 2005; Shi et al., 1997), where granzymes A
and B (and orphan granzymes) induce cell death by cleav-
ing critical substrates (Heusel et al., 1994; Lieberman,
2003; Revell et al., 2005; Russell and Ley, 2002). Per-
forin-deficient (Prf1/) mice are more susceptible to the
development of spontaneous lymphomas (Smyth et al.,
2000b), suggesting that the perforin-granzyme pathway
is an important component of tumor surveillance.
Despite the fact that activated immune cells exist in
cancer patients, the immune system often fails to prevent
tumors and limit their spread (Dunn et al., 2004b). Thus,
established tumors must have developed strategies to
inhibit or evade the immune system. Sakaguchi and
colleagues first established the essential role of
CD4+CD25+ regulatory T (Treg) cells in the induction and
maintenance of peripheral tolerance to self-antigens
(Sakaguchi, 2004; Sakaguchi et al., 1995; Yamaguchi
and Sakaguchi, 2006). More recent studies have impli-
cated Treg cells in inducing tolerance to tumors (von
Boehmer, 2005; Yamaguchi and Sakaguchi, 2006; Zou,
2006). For example, adoptively transferred Treg cells
can inhibit tumor-specific CD8+ T cell-mediated immunity
(Antony et al., 2005; Turk et al., 2004). Furthermore, Treg
cells have been shown to suppress NK cell-mediated re-
jection of transplanted tumor cells or bone-marrow grafts
(Barao et al., 2006; Ghiringhelli et al., 2005).
Treg cells may use the perforin-granzyme pathway as
a mechanism to suppress the function of immune cells
by killing them. Grossman et al. demonstrate that acti-
vated human Treg cells expressed granzyme A and/or B
and could kill various autologous immune cells in a per-
forin-dependent but FasL-independent fashion (Gross-
man et al., 2004a). In addition, Zhao et al. report that
activated murine Treg cells suppressed B cell proliferation
in a granzyme B- and perforin-dependent fashion (Zhao
et al., 2006), whereas Gondek et al. report that activatedImmunity 27, 635–646, October 2007 ª2007 Elsevier Inc. 635
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via a granzyme B-dependent, but perforin-independent,
mechanism (Gondek et al., 2005). Importantly, all of these
studies utilized in vitro methods to activate Treg cells. It is
not yet clear whether Treg cells activated in vivo express
granzymes, and if so, whether these molecules are impor-
tant for Treg cell-mediated suppression of antitumor
immune responses.
In this study, we examined the roles of perforin and
granzymes for tumor clearance in congenic 129/SvJ
mice, by using RMAS lymphoma and B16 melanoma cell
lines (both derived from B6 mice) and an acute myeloid
leukemia (AML) cell line developed in the 129/SvJ strain.
We have found that these tumor cells induced granzyme
B (but not granzyme A) expression in Treg cells, which in
turn utilized granzyme B to suppress tumor clearance me-
diated by NK and/or CD8+ T cells. Granzyme B deficiency
(Gzmb/) appears to reduce the function of Treg cells
more than that of NK and/or CD8+ T cells; these immune
effectors can utilize granzyme A and/or other mechanisms
to kill tumor cells and are not completely disabled by gran-
zyme B deficiency. As a consequence, Gzmb/ mice
clear these tumors more efficiently than do wild-type
(WT) mice. A series of experiments demonstrated that
this phenotype is Treg cell dependent and that granzyme
B and perforin are important for the ability of Treg cells to
suppress NK and/or CD8+ T cell-mediated antitumor re-
sponses.
RESULTS
Gzmb/Mice Clear Allogeneic Tumor Cells More
Efficiently than Do WT Mice
The RMAS lymphoma and B16 melanoma cell lines were
derived from C57BL/6 (B6) mice (H-2b, I-Ab) and express
very low amounts of MHC class I and no detectable
MHC class II (Figure S1A in the Supplemental Data avail-
able online). NK cell-deficient B6 mice have defects in
clearing RMAS and B16 cells (Kim et al., 2000). Because
all of our granzyme mutations were made and maintained
in congenic 129/SvJ mice (also H-2b, I-Ab), we first evalu-
ated whether the minor histocompatibility differences be-
tween the B6-derived RMAS and B16 cell lines and the
129/SvJ mice would affect the ability of these cell lines
to be cleared in an NK cell-dependent fashion. By using
a well-established strategy to deplete NK cells by intrave-
nous (i.v.) injection of anti-asialo GM1 antiserum, we de-
termined that clearance of both RMAS and B16 tumor
cells in the pure 129/SvJ strain is NK cell dependent (Fig-
ures S1B and S1C). However, CD8+ T cell-depleted mice
also displayed reduced survival after RMAS challenge
(Figure S1B), suggesting that minor histocompatibility
differences can induce CD8+ T cell-mediated clearance
of these tumor cells.
To define the roles of perforin and granzymes for the
clearance of these cell lines, several doses of RMAS cells
were used to challenge the mice. The survival curves after
i.v. injection of 13 105 and 23 105 RMAS cells are shown
in Figures 1A and 1B, respectively. Prf1/mice and gran-636 Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc.zyme AxB-deficient (Gzma/Gzmb/) mice both ex-
hibited significantly reduced survival compared to WT
mice (p < 0.0001); the survival of Prf1/ mice was less
than that of Gzma/Gzmb/ mice (p < 0.05 at both
doses). The survival of Gzma/ mice was similar to that
Figure 1. Gzmb/ Mice Have Improved Survival after RMAS
or B16 Tumor Challenge
(A) Kaplan-Meier survival curves of 129/SvJ WT mice versus strain-
matched mice deficient for the indicated granzymes (Gzm) or perforin
(Prf1), after intravenous injection with 1 3 105 RMAS lymphoma cells.
(B) Kaplan-Meier survival curves of 129/SvJ WT mice versus mice de-
ficient for the indicated granzymes or perforin, after intravenous injec-
tion with 2 3 105 RMAS lymphoma cells (LD50 for WT mice).
(C) Kaplan-Meier survival curves of 129/SvJ WT mice versus mice de-
ficient for the indicated granzymes or perforin, after intravenous injec-
tion of 3 3 105 B16 melanoma cells (LD50 for WT mice).
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more resistant to RMAS cells than did WT mice (p < 0.01;
Figures 1A and 1B). Similar patterns were found with mice
challenged with 33 105 B16 cells (Figure 1C), except that
the survival of Prf1/ mice and Gzma/Gzmb/ mice
was not statistically different.
Because RMAS clearance in the 129/SvJ strain is influ-
enced by both NK and CD8+ T cells (Figure S1), we used
flow cytometry to examine granzyme A and B expression
in DX5+CD3NK and CD8+ T cells isolated from the tumor
environments (both ascites fluid after intraperitoneal [i.p.]
tumor injection and tumor-infiltrated livers and/or lungs af-
ter i.v. tumor injection). Within the NK cell compartment,
granzyme A expression was constitutive and did not
change after RMAS challenge; in contrast, granzyme B
was detected in only 1%–5% of resting NK cells from
the spleens, livers, or lungs of naive mice (Fehniger
et al., 2007). 10%–40% of NK cells in the tumor environ-
ments expressed substantial amounts of granzyme B 4–
14 days after RMAS or B16 tumor challenge (Figure S2
and data not shown). Within the CD8+ T cell compartment,
neither granzymeA nor Bwas detected before tumor chal-
lenge; both were detected in 10%–50% of CD8+ T cells
found in the tumor environments 4–14 days after tumor
challenge (Figure S3 and data not shown). Because
Gzma/Gzmb/ mice were more susceptible than WT
mice to these tumors (Figure 1), these data suggest that
NK and/or CD8+ T cells utilize granzymes A and B to clear
these tumor cells in vivo. Recent data from our laboratory,
using in vitro activated NK cells derived from the same
mouse strains, are consistent with these findings (Feh-
niger et al., 2007).
Granzyme B Is Expressed in Allogeneic
Tumor-Activated Treg Cells
Previously, our laboratory demonstrated that activated
human Treg cells can use the perforin-granzyme pathway
to kill a variety of autologous immune cells in vitro (Gross-
man et al., 2004a). To explain the increased survival of
Gzmb/mice challenged with RMAS or B16 tumor cells,
we hypothesized that these tumor cells may induce gran-
zyme B expression in Treg cells, which in turn utilize this
enzyme to suppress the NK and CD8+ T cells that are re-
sponsible for clearing these tumors. To test this hypothe-
sis, we assessed the impact of Treg cell depletion with
a CD25 antibody (PC61) injected before the tumor chal-
lenge. Treg cell-depleted mice cleared RMAS cells more
efficiently than did mice treated with an isotype control
(Figure 2A).
In addition, we used flow cytometry to evaluate gran-
zyme expression in CD4+Foxp3+ Treg cells (Fontenot
et al., 2003; Hori et al., 2003; Khattri et al., 2003) isolated
directly from the tumor environments (ascites fluid after
i.p. injection or tumor-infiltrated livers and/or lungs after
i.v. injection). Granzyme B, but not granzyme A, was de-
tected in 5%–30% of CD4+Foxp3+ Treg cells found in
the ascites fluid of mice bearing RMAS tumor cells for 4–
14 days (Figures 2B and 2C); very similar granzyme B ex-
pression patterns were found in the Treg cells in tumor-in-filtrated livers and/or lungs after i.v. injection with RMAS or
B16 cells (data not shown). In contrast, very few granzyme
B-expressing Treg cells were found in the spleens
(Figure S4) or peripheral lymph nodes of tumor-bearing
mice, or in the spleens, livers, or lungs of naive mice
(<1%, data not shown). To confirm these flow cytometry
results, we purified Treg cells from the ascites fluid of
RMAS tumor-injected mice and performed immunofluo-
rescence (IF) studies. Granzyme B was detected in the
granules of Treg cells derived from the tumor ascites fluid,
but not from Treg cells derived from the spleens of naive
mice (Figure S5). Perforin was not detected by flow cyto-
metric methods in the same Treg cells and NK cells that
were found to express granzyme B (data not shown), by
means of an antibody that is capable of detecting perforin
in NK cells activated in vitro, and NK cells isolated from
MCMV-infected mice (Fehniger et al., 2007). However,
the sensitivity of this antibody was relatively low, because
we have shown that cells expressing minimal amounts of
perforin (as defined by this antibody) are still capable of
killing target cells in a perforin-dependent fashion (Feh-
niger et al., 2007).
Enhanced Clearance of a Syngeneic Tumor Cell
Line in Treg Cell-Depleted Mice
To determine whether the enhanced tumor clearance in
Gzmb/ mice is also observed with a syngeneic tumor
challenge, we developed a tumor cell line from 129/SvJ
mice, via an established retroviral transduction strategy
(Luo et al., 2005). In brief, bone-marrow cells harvested
from two female 129/SvJ mice were transduced with an
MSCV-Myc-IRES-Bcl2 construct as described (Luo
et al., 2005). Myc-Bcl2 immortalized cells (MB0) were im-
munophenotyped with flow cytometry (Figure 3A). Com-
pared to primary 129/SvJ splenocytes, MB0 cells ex-
pressed relatively low amounts of MHC I (H-2Kb) and
were negative for MHC II (I-Ab). MB0 cells were Gr-1 pos-
itive and negative for lymphoid markers (CD3, B220). 129/
SvJ WT mice injected with MB0 cells developed AML-like
histopathology (data not shown). To determine whether
Treg cells play a role in the clearance of these tumor cells
in 129/SvJ mice, we depleted Treg cells from these ani-
mals with a CD25 antibody (PC61), as described above.
The Treg cell-depleted mice cleared MB0 cells more effi-
ciently than did mice treated with an isotype control
(Figure 3B), suggesting that Treg cells suppress the clear-
ance of these syngeneic tumor cells in vivo.
Granzyme B Expression in Treg Cells Activated
by a Syngeneic Tumor Cell Line
We used flow cytometry to evaluate granzyme expression
in CD4+Foxp3+ Treg cells isolated directly from the
MB0 tumor environment (ascites fluid after i.p. injection).
Granzyme B, but not granzyme A, was detected in
CD4+Foxp3+ Treg cells in the tumor ascites fluid (Figures
4A and 4B). However, MB0 cells induced granzyme B ex-
pression in Treg cells with delayed kinetics compared to
that of RMAS cells, suggesting that the allogeneic signalsImmunity 27, 635–646, October 2007 ª2007 Elsevier Inc. 637
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Associated Treg Cells
(A) 129/SvJ WT mice were depleted of Treg cells by PC61 antibody injection as described in the Experimental Procedures. Kaplan-Meier survival
curves of Treg cell-depleted mice versus mice treated with an isotype control antibody, after intravenous injection with 2.5 3 105 RMAS cells.
(B) 1 3 106 RMAS cells were injected intraperitoneally, and ascites fluid was collected at the indicated times and analyzed by flow cytometry.
CD4+Foxp3+ cells were examined for the expression of granzymes B and A. Representative flow cytometry plots of cells derived from tumor ascites
of individual mice are shown.
(C) Summary scatter plots of the percentage of CD4+Foxp3+ Treg cells positive for granzyme B or A in the tumor ascites are shown, with each data
point representing an individual mouse. Horizontal bars represent the average percentage of granzyme B- or A-positive Treg cells. Two-tailed t tests
were used to determine statistical significance between day 0 and the indicated time points (*p < 0.05, **p < 0.01, ***p < 0.001).caused by minor histocompatibility differences induce
more rapid activation of Treg cells.
Because MB0 cells overexpress Bcl-2, and because
granzyme B-induced target cell death is inhibited by Bcl-
2 (Goping et al., 2003; Jans et al., 1999; Sutton et al.,
2003), this cell line is expected to be relatively resistant
to granzyme B-mediated killing. We would predict that if
granzyme B was relevant only in the NK and/or CD8+ T
cell effector arm, granzymeBdeficiencywould have amin-
imal impact on the clearance of MB0 cells in vivo. Instead,
we found that Gzmb/mice cleared MB0 cells more effi-
ciently than did WT mice, consistent with a predominant
effect of granzymeB in the Treg cell compartment (Figures
4C and 4D).
Adoptively Transferred Treg Cells Suppress
Tumor Clearance in a Granzyme B- and Perforin-
Dependent Fashion
To directly monitor tumor cell clearance in vivo, we trans-
duced RMAS cells with a retroviral vector containing
a click beetle red (CBR) luciferase-GFP fusion cDNA,638 Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc.and we used bioluminescence imaging to serially monitor
mice injected intraperitoneally with these cells (Figure 5A).
With this method, we quantified the clearance of RMAS
cells in vivo and found that Gzmb/ mice cleared
RMAS cells more rapidly than did WT mice. As predicted,
Prf1/mice andGzma/Gzmb/mice exhibited a trend
toward reduced tumor clearance (Figure 5B; Figure S6).
Three independent luciferase-expressing RMAS clones
were completely cleared in WT mice by day 14, even
when 2–8 3 106 cells were injected (data not shown);
the transduced RMAS clones expressed high amounts
of CBR luciferase and GFP, which presumably induced
more potent rejection after the first week of tumor growth
in the mice. However, the evaluation of tumor clearance
during the early phase (days 0–7) of the antitumor re-
sponse (Figure 5B; Figure S6) in the various knockout
strains correlated well with the survival curves of the
mice receiving the nontransduced RMAS cells (Figures
1A and 1B). MB0 cells were resistant to secondary viral
transductions with the luciferase-GFP retroviral vector
and could not be further evaluated with this assay.
Immunity
Granzyme B- and Perforin-Dependent Treg FunctionFigure 3. Treg Cell-Depleted Mice Have Improved Survival after Injection of a Syngeneic AML Cell Line
(A) 129/SvJ bone-marrow cells were transduced with an MSCV-Myc-IRES-Bcl2 construct as described in the Experimental Procedures, and the cell
line MB0 was generated by serial passaging in vitro. MB0 cells were characterized by flow cytometry for the expression of Bcl2, myeloid (Gr-1), and
lymphoid markers (CD3, B220), and MHC class I and II (H-2Kb, I-Ab). Wright-Giemsa-stained MB0 cells are also shown.
(B) Kaplan-Meier survival curves of 129/SvJWTmice depleted of Treg cells versus mice treated with an isotype control antibody, after intraperitoneal
injection with 5 3 105 MB0 AML cells.To determine whether Treg cells can suppress tumor
clearance in vivo, we adoptively transferred naive WT
Treg cells and luciferase-expressing RMAS cells into
Gzmb/ mice. A series of imaging studies with lucifer-
ase-expressing RMAS cells (at doses of 3 3 105, 6 3
105, 13 106, 23 106, 43 106, and 83106 cells) indicated
that a dose of 2 3 106 cells reproducibly established the
difference in tumor clearance between WT and Gzmb/
mice (Figures 5B and 5C; Figure S6; and data not shown).
By using MACS purification techniques (Miltenyi Biotec),
we isolated CD4+CD25+ Treg cells from the spleens of na-
ive mice for adoptive transfer experiments. The purity of
these cells (as determined by post-sort FACS analysis)
was consistently above 95%; more than 90% of the puri-
fied CD4+CD25+ T cells were shown to be Foxp3+
(Figure S7). To determine the optimal Treg cell dose for
adoptive transfer, we simultaneously injected 5 3 105,
1 3 106, or 2 3 106 WT Treg cells with 2 3 106 luciferase-
expressingRMAScells into theperitoneal cavity ofGzmb/
mice. Tumor clearance was assessed sequentially by
bioluminescence imaging. Compared to Gzmb/ mice
that received RMAS cells only, adoptive transfer of 5 3
105 Treg cells showed no effect on clearance, 1 3 106
Treg cells exhibited slightly delayed clearance (data not
shown), and 2 3 106 Treg cells significantly suppressed
RMAS clearance (Figure 5C). We performed three inde-
pendent adoptive transfer experiments with identical
conditions and pooled the data for analysis (Figure 5C).
Adoptive transfer of WT Treg cells into Gzmb/ mice
restored tumor growth to about 40% of that observed in
WT mice. Transfer of equal doses of Gzmb/ Treg cells
(Figure 5C) or Prf1/ Treg cells (Figure 5D) had no signif-
icant effect on tumor growth, suggesting that granzyme
B and perforin are both required for Treg cell-mediated
suppression of tumor clearance in this model system.The adoptive transfer of 2 3 106 naive WT Treg cells
showed no effect on the survival of Gzmb/ mice; how-
ever, this dose of Treg cells produced only partial restora-
tion of tumor growth. Because only small numbers of Treg
cells could be purified from naive spleens (about 7 3 105
cells per spleen), we were not able to purify adequate
numbers of cells for a large study designed to assess
survival outcomes.
NK and CD8+ T Cell Death in Tumor Ascites Is Treg
Cell Dependent
We hypothesized that NK and CD8+ T cells might be ‘‘sup-
pressed’’ by being killed by Treg cells in the tumor environ-
ment. To test this hypothesis, we performed ex vivo ex-
periments to assess NK and T cell death in tumor
ascites fluid. We collected tumor ascites fluid from WT
mice, Prf1/mice, andGzmb/mice 5 days after i.p. in-
jection of RMAS cells and immediately stained the cells
with 7-AAD to assess cell death. Fewer than 5% of
DX5+CD3 NK cells or CD8+ T cells in the tumor ascites
fluid of all three genotypes were 7-AAD positive (data
not shown). Because the ingestion of apoptotic cells by
peritoneal macrophages could potentially mask our ability
to detect apoptotic cells in vivo, we decided to first de-
plete adherent cells by incubating the tumor ascites fluid
on tissue culture plates for 40 min at 37C (Kobayashi
et al., 1990; Law et al., 1989). The nonadherent cells
were either directly stained with 7-AAD at time 0 or incu-
bated for 3 hr at 37C before 7-AAD staining. Immediately
after depletion of adherent cells, fewer than 5% of NK or T
cells in the tumor ascites of all three genotypes were 7-
AAD positive (data not shown); after the 3 hr incubation,
however, about 30% of NK and CD8+ T cells in the tumor
ascites of WT mice became 7-AAD positive (Figures 6A–
6C). Importantly, NK and CD8+ T cell death wasImmunity 27, 635–646, October 2007 ª2007 Elsevier Inc. 639
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(A) 1 3 106 MB0 AML cells were injected intraperitoneally, and ascites fluid was collected at the indicated times and analyzed by flow cytometry.
CD4+Foxp3+ cells were examined for the expression of granzymes B and A. Representative flow cytometry plots of cells derived from MB0 AML
tumor ascites of individual mice are shown.
(B) Summary scatter plots of the percentage of CD4+Foxp3+ Treg cells positive for granzyme B or A in the MB0 tumor ascites are shown, with each
data point representing an individual mouse. Horizontal bars represent the average percentage of granzyme B- or A-positive Treg cells. Two-tailed t
tests were used to determine statistical significance between day 0 and the indicated time points (*p < 0.05, **p < 0.01, ***p < 0.001).
(C) Kaplan-Meier survival curves of 129/SvJ WT mice versus Gzmb/ mice or Gzma/ mice, after intraperitoneal injection with 5 3 105 MB0 AML
cells.
(D) Kaplan-Meier survival curves of 129/SvJ WT mice versus Gzmb/ mice or Gzma/ mice, after intraperitoneal injection with 1 3 106 MB0 AML
cells.significantly reduced in the tumor ascites of Gzmb/
mice and Prf1/ mice. In contrast, less than 5% of
CD4+CD25+ Treg cells in the same ascites samples of all
three genotypes were 7-AAD positive at time 0 (data not
shown) or after 3 hr incubation (Figures 6B and 6C). To as-
sess background cell death in this system, we isolated640 Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc.control peritoneal fluids from naive, noninjected WT
mice (n = 3), Gzmb/ mice (n = 3), and Prf1/ mice
(n = 3); spontaneous 7-AAD positivity in the control perito-
neal fluids (for all three genotypes) was consistently low
for NK cells (6.8% ± 1%, n = 9), CD8+ T cells (6.3% ±
1.6%, n = 9), and Treg cells (4.8% ± 1.5%, n = 9). To
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Granzyme B- and Perforin-Dependent Treg FunctionFigure 5. Adoptively Transferred WT, but Not Gzmb/ or Prf1/, Treg Cells Suppress RMAS Tumor Clearance in Gzmb/Mice
(A) 2 3 106 click beetle red luciferase-expressing RMAS cells were injected intraperitoneally into WT mice, various Gzm/ mice, and Prf1/ mice.
Bioluminescence imaging was performed to serially assess whole-body tumor clearance in each mouse, with luciferase activity as a measure for
tumor burden. Representative imaging time course of individual mice from each genotype is shown, with the same scale of photon flux indicating
luciferase activity.
(B) Summaries of tumor burdens for all genotypes are shown asmean ± SEM, after i.p. injection of 23 106 luciferase-expressing RMAS cells, with 4–5
mice assessed in each genotype. Data points are shown as mean ± SEM, and two-tailed t tests were used to determine statistical significance be-
tween WT mice and mice deficient for the indicated granzymes or perforin (*p < 0.05).
(C) A summary of three independent adoptive transfer experiments, with nine mice assessed in each group. Abbreviations: WT, WT mice receiving
only tumor cells, as a control for tumor outgrowth in these mice; Gzmb/, Gzmb/mice receiving only tumor cells, as a control to demonstrate the
reduced tumor growth in these animals; Gzmb/ + WT Treg, Gzmb/ mice adoptively transferred with WT Treg cells, in addition to tumor cells;
Gzmb/ + Gzmb/ Treg, Gzmb/ mice adoptively transferred with Gzmb/ Treg cells, in addition to tumor cells.
(D) A summary of two independent adoptive transfer experiments is shown (n = 6 in each group). Abbreviation: Gzmb/ + Prf1/ Treg, Gzmb/
mice adoptively transferred with Prf1/ Treg cells, in addition to tumor cells. Data points are shown as mean ± SEM, and two-tailed t tests were
used to determine statistical significance (*p < 0.05).determine whether Treg cells are relevant for the death of
NK and CD8+ T cells in the tumor ascites fluid, we de-
pleted Treg cells from mice by injecting PC61 CD25 anti-
body 4 and 2 days prior to injection with tumor cells.
This strategy depleted the majority of CD4+Foxp3+ Treg
cells (72% ± 7%, n = 18) in the tumor ascites fluid (data
not shown); NK and CD8+ T cell death in the Treg cell-
depleted tumor ascites of WT mice was reduced by
more than 70% (p < 0.01, n = 6) (Figures 6A and 6C). Taken
together, these data suggest that Treg cells can induce ef-
fector cell death in the tumor environment by a granzymeB- and perforin-dependent mechanism. Additionally, NK
and CD8+ T cell death in the tumor ascites of Gzmb/
mice and Prf1/ mice was further reduced after Treg
cell depletion (Figures 6A and 6C), suggesting that addi-
tional mechanisms may contribute to Treg cell-mediated
suppression of NK and CD8+ T cells. Absolute NK and
CD8+ T cell numbers in the ascites fluid of the WT mice,
Gzmb/mice, and Prf1/mice were difficult to compare
at any given time, because the numbers of tumor cells in
the ascites fluid of these mice were so drastically different
(Figures 5B and 6A; Figure S6).Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc. 641
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Mice
WTmice,Gzmb/mice, and Prf1/mice were treated with intraperitoneal injections of 500 mg of PC61 CD25 monoclonal antibody to deplete Treg
cells (TrD), or rat IgG1 as a control, on days 4 and 2 prior to intraperitoneal injection of 13 106 RMAS cells. On day 5 after tumor injection, tumor
asciteswas collected and depleted of adherent cells. As a negative control (Neg), peritoneal fluidwas isolated from naive, noninjectedWTmice (n = 3),
Gzmb/mice (n = 3), and Prf1/mice (n = 3) and treated identically. Nonadherent cells were incubated in V-bottom 96-well plates for 3 hr, followed
by staining with cell-surface markers and 7-AAD to assess cell death in the NK, CD8+ T, and Treg compartments by flow cytometry.642 Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc.
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Granzyme B and Perforin in Treg Cell-
Mediated Suppression of Antitumor NK
and CD8+ T Cells
Left: In wild-type mice, RMAS, B16, and MB0
AML tumors induce granzyme B expression
in Treg cells by an unknown mechanism (indi-
cated by the dashed line). Activated Treg cells
utilize granzyme B and perforin to suppress NK
cell and/or CD8+ T cell-mediated antitumor im-
munity in vivo. NK cells and CD8+ T cells use
the perforin-granzyme pathway, as well as per-
forin- and granzyme-independent mecha-
nisms, to kill tumor cells in vivo.
Center: In granzyme B-deficient mice, Treg
cells are missing a key molecule that is
necessary to suppress the function of NK cells and CD8+ T cells. However, the effector cells can use alternative mechanisms to kill the tumors,
and therefore these mice are relatively resistant to tumor outgrowth.
Right: In mice deficient for perforin or granzymes A and B, both regulatory and effector cells are functionally disabled. Tumor cells can proliferate
because they cannot be controlled by the alternative killing mechanisms of the effectors, even though they are not suppressed by Treg cells.DISCUSSION
By using congenic 129/SvJ mice deficient for perforin or
granzymes as hosts, we have studied the clearance of
three independent tumor cell lines in vivo. RMAS and
B16 cells (derived from B6 mice) share the same MHC I
and II as 129/SvJ mice but have minor histocompatibility
differences. In contrast, the MB0 cell line was derived
from the bone-marrow cells of 129/SvJ mice and is there-
fore syngeneic with the hosts. Surprisingly,Gzmb/mice
cleared all of these tumors more efficiently than did WT
mice; Treg cell-depleted mice also displayed enhanced
tumor clearance. These results suggested that Treg cells
might suppress antitumor immune responses via a gran-
zyme B-dependent mechanism. We indeed found that
granzyme B (but not granzyme A) was highly induced in
Treg cells in the tumor environment. Adoptive transfer of
purified Treg cells directly demonstrated that granzyme
B and perforin are required for Treg cell-mediated sup-
pression of the antitumor response against RMAS cells.
Ex vivo evaluation of in vivo activated NK and T cells sug-
gested that tumor-activated Treg cells can cause the
death of NK and CD8+ T cells in a granzyme B- and per-
forin-dependent fashion. Taken together, these results
suggest that these tumors can induce granzymeB expres-
sion in Treg cells, which then utilize this protease to induce
the death of NK and/or CD8+ T cells, thereby suppressing
antitumor immunity (Figure 7). By activating granzyme B
in Treg cells, these tumor cells gain a survival advantage,but this advantage is lost in the setting of granzyme B
deficiency.
The studies described here suggest that Treg cells can
suppress the ability of NK and CD8+ T cells to clear tumors
in vivo. Recent reports from two other groups have also
shown that Treg cells can suppress NK cell-mediated im-
mune responses (Ghiringhelli et al., 2005; Barao et al.,
2006). In one model, Treg cells were shown to suppress
NK cell proliferation and function via membrane-bound
TGF-b; TGF-b-deficient Treg cells failed to suppress (Ghir-
inghelli et al., 2005). In a bone-marrow transplant model,
Treg cells were likewise shown to suppress NK cell-medi-
ated rejection of transplanted BM cells via a TGF-b-
dependent mechanism; neutralizing TGF-b antibodies in-
creased NK cell-mediated rejection of BM grafts (Barao
et al., 2006). Neither of these studies specifically ad-
dressed the role of the perforin-granzyme pathway for
Treg cell-mediated NK suppression in these experimental
settings. However, it is important to note that TGF-b can
influence the expression of perforin and granzymes,
thereby altering the function of cytotoxic lymphocytes
(Thomas and Massague, 2005). The effect of TGF-b on
perforin and granzyme expression in Treg cells has not
yet been defined but is under investigation.
In the model systems described in this study, granzyme
B and perforin were shown to be important for the ability
of Treg cells to suppress NK and CD8+ T cell activity.
Recent studies from our laboratory and others have sug-
gested that human and mouse Treg cells can use the(A) Representative flow cytometry plots showing the percentage of 7-AAD-positive DX5+CD3 NK cells in the tumor ascites fluid from individual mice
with the indicated genotypes, with or without in vivo depletion of Treg cells (TrD). The black dashed lines (on the right side the lymphocyte gates)
indicate the position of the RMAS tumor cells.
(B) Representative flow cytometry plots showing the percentage of 7-AAD-positive CD4+CD25+ Treg cells and CD8+ T cells in the tumor ascites fluid
from an individual WT mouse without in vivo depletion of Treg cells. CD4 and CD25 were used as Treg surface markers because intracellular staining
(with Foxp3) precludes live-cell analysis with 7-AAD.
(C) A summary of pooled data from three independent experiments is shown (n = 2 in each experimental group, 6 total mice). Spontaneous death of
NK cells (6.8% ± 1%, n = 9), of Treg cells (4.8% ± 1.5%, n = 9), and of CD8+ T cells (6.3% ± 1.6%, n = 9) in the noninjected control peritoneal fluid was
subtracted to provide specific cytotoxicity data. Data points are shown as mean ± SEM, and two-tailed t tests were used to determine statistical
significance (*p < 0.05, **p < 0.01, ***p < 0.001).Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc. 643
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nism of suppression (Grossman et al., 2004a; Zhao et al.,
2006). Previous reports also demonstrated the expression
of granzyme B in purified murine CD4+CD25+ Treg cells
that were activated in vitro by TCR ligation and IL-2 (Gon-
dek et al., 2005; Zhao et al., 2006). However, as noted
above, several different mechanisms are potentially rele-
vant for Treg cell-mediated immune suppression, includ-
ing cytokine-mediated (e.g., TGF-b, IL-10) as well as
cell-surface molecule-dependent inhibition of T cells and
APCs (e.g., GITR and CTLA4) (von Boehmer, 2005; Zou,
2006). The exact contribution of each pathway to overall
Treg suppressive activity may be context and/or model
dependent; however, it is also possible that Treg cells
may use several mechanisms simultaneously to provide
‘‘fail-safe’’ suppression of activated immune cells, which
can damage the host if uncontrolled.
Our studies suggest that Treg cells may suppress NK
and CD8+ T cells by killing them. The system that we
used to demonstrate this finding relies upon the activation
of T cells and NK cells in vivo, followed by depletion of ad-
herent cells (to prevent the ingestion of newly apoptotic
cells), followed by ex vivo incubation to allow the activated
cells to interact. The day 5 ascites fluid contains a complex
mixture of cells, but it is probable that NK and CD8+ T cell
death in this setting is Treg cell dependent (because de-
pletion of Treg cells with the PC61 CD25 antibody reduces
NK and CD8+ T cell death). Further, our data suggest that
both granzyme B and perforin are relevant for this pheno-
type, because deficiency of either reduces NK and CD8+ T
cell death. However, the reduction in NK and CD8+ T cell
death was not as pronounced with perforin or granzyme
B deficiency as it was with Treg cell depletion, suggesting
that Treg cells must use additional pathways to cause
suppression and/or death to NK and CD8+ T cells. Be-
cause these experiments involved a complex mixture of
peritoneal cells, we do not knowwhether Treg cells induce
NK and CD8+ T cell death via a direct or an indirect mech-
anism. To answer this question definitively, we will need to
define the precise signals that tumor cells use to activate
Treg cells, NK cells, andCD8+ T cells in vivo and use highly
purified populations of these activated cells to explore
a direct killing mechanism. However, because the per-
forin-granzyme system is contact dependent and capable
of directly causing target cell death, it seems possible to
us that Treg cells may suppress NK and CD8+ T cell func-
tion in this setting by directly causing their death. How-
ever, our data suggests that activated Treg cells do not
kill tumor cells, because depletion of Treg cells improved
the survival of tumor-bearing mice.
Granzyme B deficiency decreases Treg cell function
more than it reduces the function of antitumor NK and
CD8+ T cells in vivo. Recent studies from our lab have
shown that granzyme B plays a major role in the ability
of IL-15-activated NK cells to kill their targets (Fehniger
et al., 2007); however, the in vivo activation of NK and
CD8+ T cells by tumors may invoke additional killing path-
ways. Indeed, granzyme B-independent mechanisms are
clearly capable of providing NK cell-mediated tumor644 Immunity 27, 635–646, October 2007 ª2007 Elsevier Inc.clearance (Grundy et al., 2007; Rosen et al., 2000; Scre-
panti et al., 2001).
In summary, the perforin-granzyme pathway is impor-
tant not only for the function of NK and CD8+ T cells, but
it may also be utilized by Treg cells to suppress the ac-
tivity of these same cells (Figure 7). It will be important
to determine whether Treg cells can use the perforin-
granzyme B pathway to suppress other immune cells in
vivo, such as CD4+CD25 T cells and B cells; alternative
model systems will be required to address these ques-
tions in the future.
EXPERIMENTAL PROCEDURES
Animals and Tumor Cell Lines
WT129/SvJmicewere obtained from the Jackson Laboratory.Gzma/
mice were generated as described (Shresta et al., 1997). Gzmb/
mice were generated as described (Heusel et al., 1994; Revell et al.,
2005). Both Gzma/ mice and Gzmb/ mice were generated and
maintained in congenic 129/SvJ mice (H-2b, I-Ab). Gzma/Gzmb/
mice were generated by crossing Gzma/ mice with Gzmb/ mice,
followed by genotyping with Southern and PCR strategies. Prf1/
mice were developed by a speed congenic strategy to backcross
B6J mice containing the ‘‘Kagi’’ mutation to 129/SvJ mice for eight
generations; >98% of the congenic markers tested were from the
129/SvJ strain in themice that were used to generate the breeding col-
ony of these mice. RMAS lymphoma and B16 melanoma cell lines,
which were originally derived fromC57BL/6mice (H-2b, I-Ab), were ob-
tained from W. Yokoyama and maintained in complete K10 medium
(Fehniger et al., 2007). The MB0 acute myeloid leukemia (AML) cell
line was developed from 129/SvJ mice by an established retroviral
transduction strategy (Luo et al., 2005). In brief, bone-marrow cells har-
vested from two female 129/SvJmice were transduced with anMSCV-
Myc-IRES-Bcl2 construct as described (Luo et al., 2005). Myc-Bcl2
immortalized cells (MB0) were passaged in regular K10 medium (with-
out additional growth factors) for 3 months before injection for survival
and granzyme expression studies. All mice were bred and maintained
in SPF housing, and all experiments were conducted in accordance
withWashington University School of Medicine animal care guidelines,
via protocols approved by the animal studies committee.
Reagents and Antibodies
The anti-asialo GM1 antiserum was purchased fromWako Chemicals.
The purified CD25 antibody (PC61) and rat IgG1 isotype control
(HRPN), CD8 antibody (53-6.7), and rat IgG2a isotype control (C1.18)
were purchased from Bio Express. The CD4+CD25+ Treg isolation
kits were purchased from Miltenyi Biotec. Antibodies used include
anti-mouse CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD25
(7D4, PC61), CD49b (DX5), CD16/32 (2.4G2), Bcl-2 (3F11) (BD Biosci-
ences), Foxp3 (eBioscience, FJK-16 s), and granzyme B (Caltag,
GB12). The anti-mouse granzyme A monoclonal antibody was pro-
duced in our laboratory and is now available from Santa Cruz (3G8.5).
Tumor Challenge and Survival Study
Tumor cells were washed twice in RPMI 1640 by centrifuging for 5 min
at 300 3 g and were then resuspended in RPMI 1640 at appropriate
concentrations. For survival studies, all WT mice, Gzm/ mice, and
Prf1/ mice were injected in the lateral tail vein with 1 3 105, 2 3
105, or 2.53 105 RMAS lymphoma cells, or 23 105 or 33 105 B16mel-
anoma cells in 200 ml RPMI 1640 on day 0. All mice were monitored
over a 60 day period. For theMB0 tumor challenge, mice were injected
i.p. with 5 3 105 or 1 3 106 cells. Mice were sacrificed when they
gained more than 25% body weight and/or become moribund. To de-
termine the impact of Treg cell depletion on survival, 500 mg of purified
PC61 CD25 monoclonal antibody (or rat IgG1 isotype control) was ad-
ministered by intraperitoneal injection 2 days prior to tumor injection
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monoclonal antibody (53-6.7) or rat IgG2a isotype control was admin-
istered similarly to determine its effect on the survival of mice chal-
lenged with RMAS cells. Kaplan-Meier survival analysis was per-
formed with Prism software (Graph Pad, San Diego, CA).
Cell Isolation
Lymphocytes were isolated from the tumor environment, which in-
cludes ascites fluid after i.p. tumor injection or tumor-infiltrated livers
and/or lungs after i.v. tumor injection and the spleens and peripheral
lymph nodes of tumor-bearing mice (which were not infiltrated by tu-
mor cells). As controls, the peritoneal fluid, spleens, livers, and lungs
of naive mice were also collected as described (Grossman et al.,
2004b; Heusel et al., 1994; Revell et al., 2005).
Intracellular Staining and Flow Cytometry
1 3 106 cells were washed and resuspended in staining buffer (PBS,
0.5% bovine serum albumin, 0.5 mM EDTA). Samples were labeled
with primary-conjugated antibodies against cell-surface markers
(anti-mouse CD3, CD4, CD8, CD25, DX5) (BD Biosciences). Samples
were fixed, permeabilized (Foxp3 staining kit, eBioscience), and
stained with primary-conjugated anti-granzyme A antibody (3G8.5;
Santa Cruz), and/or primary-conjugated anti-granzyme B antibody
(GB12; Caltag), and/or primary-conjugated anti-Foxp3 antibody
(FJK-16 s; eBioscience) diluted at 1:400 in staining buffer. Sample
data were acquired on a Cytek-modified FACScan (Becton Dickinson)
or FC500 (Coulter) flow cytometer and analyzed with CXP (Coulter) or
FlowJo (TreeStar) software. Isotype controls were used to set quad-
rant and regional gates. All flow cytometric analyses depicted are rep-
resentative of five or moremice. Anti-granzyme A and anti-granzymeB
antibodies were analyzed for antigen specificity by knockout mouse
staining assays as described (Fehniger et al., 2007; Grossman et al.,
2004b).
Bioluminescence Imaging of In Vivo Tumor Clearance
RMAS cells were transducedwith aDU3 retroviral construct that drives
the expression of a fusion cDNA encoding click beetle red luciferase
(CBR) and green fluorescence protein (GFP). Individual GFP-positive
RMAS cells were MoFlo sorted into single wells of a 96-well plate.
The expanded clones were further screened for high luciferase expres-
sion. CBR luciferase-expressing RMAS clones were injected i.p. into
WT mice, Gzm/ mice, and Prf1/ mice in 200 ml RPMI 1640 on
day 0, and bioluminescence imaging was performed 2 hr later and var-
iously on days 2 through 21 after injection. For imaging, mice were in-
jected i.p. with D-luciferin (150 mg/g body weight), anesthetized (2%
isoflurane), and placed in an IVIS 50 imaging system (Xenogen) (expo-
sure time, 1–30 s; binning, 2–8; no filter; f/stop, 1; FOV, 12 cm) (Gross
and Piwnica-Worms, 2005). Regions of interest (ROI) were defined
manually over the whole body with Living-Image software (Igor Wave-
metrics) for determining tumor burden signal intensities. Data were ex-
pressed as photon flux (photons/s) or change from initial (post injection
image/2 hr image) across all mice receiving the same treatment.
Adoptive Transfer of CD4+CD25+ Treg Cells
CD4+CD25+ Treg cells were isolated from the resting spleens of WT
mice, Prf1/mice, and Gzm/mice with the CD4+CD25+ Treg isola-
tion kit, according to the manufacturer’s instructions (Miltenyi Biotec).
23 106 CD4+CD25+ Treg cells (>95% pure) were injected i.p. with 23
106 luciferase-expressing RMAS cells into eachGzmb/ host mouse.
Bioluminescence imaging was performed to serially assess tumor
clearance.
Flow-Based Ex Vivo NK and CD8+ T Cell Death Assay
WTmice,Gzmb/mice, and Prf1/mice were depleted of Treg cells
by intraperitoneal injection of 500 mg of PC61 CD25 monoclonal anti-
body (or rat IgG1 control antibody) on day 4 and day 2 prior to intraper-
itoneal injection of 13 106 RMAS cells. On day 5 after tumor injection,
tumor ascites fluid was harvested. To prevent the phagocytosis of ap-optotic cells, the ascites fluid was depleted of adherent cells by incu-
bating total ascites fluid on plastic tissue-culture plates for 40 min (Ko-
bayashi et al., 1990; Law et al., 1989). As a negative control, peritoneal
fluid was isolated from naive, noninjected WT mice, Gzmb/ mice,
and Prf1/mice, and treated identically. Nonadherent cells were har-
vested and incubated in V-bottom 96-well plates for 3 hr, followed by
staining with primary-conjugated antibodies against cell-surface
markers (CD3, CD4, CD8, CD25 [7D4], DX5) and 7-AAD to
assess cell death in the NK, CD8+ T, and Treg compartments by flow
cytometry.
Supplemental Data
Seven figures are available at http://www.immunity.com/cgi/content/
full/27/4/635/DC1/.
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